ACELYRIN Inc
NASDAQ:SLRN
ACELYRIN Inc
Change in Working Capital
ACELYRIN Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
ACELYRIN Inc
NASDAQ:SLRN
|
Change in Working Capital
$52.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Change in Working Capital
-$2.8B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Change in Working Capital
-$880m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Change in Working Capital
$2.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
8%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Change in Working Capital
-$514.8m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-22%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Change in Working Capital
-$618.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
ACELYRIN Inc
Glance View
ACELYRIN Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Agoura Hills, California and currently employs 51 full-time employees. The company went IPO on 2023-05-05. ACELYRIN, INC. is a late-stage clinical biopharmaceutical company. The firm is focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. Its initial focus is on the treatment of diseases with pathology related to excess activation of the immune system. The Company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit anti-interleukin (IL)-17A with high potency through tight binding affinity and the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody. The company is also advancing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R). Lonigutamab has shown high potency against IGF-1R in both binding and functional laboratory assays. In addition, the Company is developing SLRN-517, which is a fully human IgG1 monoclonal antibody targeting c-KIT.
See Also
What is ACELYRIN Inc's Change in Working Capital?
Change in Working Capital
52.1m
USD
Based on the financial report for Dec 31, 2023, ACELYRIN Inc's Change in Working Capital amounts to 52.1m USD.
You don't have any saved screeners yet